Trial Profile

A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KER 047 (Primary)
Indications Iron deficiency anaemia
Focus Adverse reactions; Pharmacodynamics
Sponsors Keros Therapeutics

Most Recent Events

27 Jun 2023 Status changed from recruiting to discontinued.
20 Apr 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
03 Mar 2023 According to a Keros Therapeutics media release, the company plans to report additional dose escalation data from this study in the second half of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com